Skip to content
OpenCapital
Get started
Standard BioTools Inc. logo

Standard BioTools Inc. (LAB) Q1 2026 Earnings

LAB·Reported May 5, 2026·After market close

Standard BioTools Inc. reported Q1 2026 revenue of $21.1M (-48.2% YoY), beat analyst consensus of $17.8M by $3.3M. Diluted EPS came in at $-0.02 (+50.0% YoY).

Revenue
$21.1Mbeat by $3.3M
Consensus: $17.8M
Diluted EPS
$-0.02met estimate
Consensus: $-0.02
SEC

SEC Filings

Earnings release8-K · 0001193125-26-206395
Quarterly report10-Q · 0001193125-26-208967

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Standard BioTools Inc.'s Q1 2026 earnings report.

Standard BioTools Inc. (LAB) reported Q1 2026 earnings on May 5, 2026 after market close.

Standard BioTools Inc. reported revenue of $21.1M and diluted EPS of $-0.02 for Q1 2026.

Revenue beat the consensus estimate of $17.8M by $3.3M. EPS beat the consensus estimate of $-0.02 by $0.00.

Compared to the same quarter a year prior, revenue declined 48.2% from $40.8M a year earlier and diluted EPS grew 50.0% from $-0.04.

You can read the 8-K earnings release (0001193125-26-206395) and the 10-Q periodic report (0001193125-26-208967) directly on SEC EDGAR. The filing index links above go to sec.gov.